Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Martens, Alexander ^a,b   Zelba, Henning ^a   Garbe, Claus ^b   Pawelec, Graham ^a   Weide, Benjamin ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Antigen specific T cells; MDSCs; Melan A; Melanoma; NY ESO 1; Prognostic marker

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; HLA DR ANTIGEN; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL INTERACTION; CELLULAR IMMUNITY; HUMAN; MELANOMA; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; PHENOTYPE; SUPPRESSOR CELL; TUMOR IMMUNITY; TUMOR VOLUME;

EID: 84899104324     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27845     Document Type: Article

References (9)

1. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012; 30:1835-41; PMID:22529253; http://dx.doi.org/10.1200/JCO.2011.40.2271.
2. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, et al. Myeloid-derived suppressor cells predict survival of advanced melanoma patients: comparison with regulatory T cells and NY-ESO-1-or Melan-A-specific T cells. Clin Cancer Res 2013; Forthcoming; PMID:24323899; http://dx.doi.org/10.1158/1078-0432.CCR-13-2508.
3. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175.
4. Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013; 73:3877-87; PMID:23633486; http://dx.doi.org/10.1158/0008-5472.CAN-12-4115.
5. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colonystimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546-53; PMID:17577033; http://dx.doi.org/10.1200/JCO.2006.08.5829.
6. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/s00262-008-0523-4.
7. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011; 118:2254-65; PMID:21734236; http://dx.doi. org/10.1182/blood-2010-12-325753.
8. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883.
9. Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, et al. Limited induction of tumor crossreactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 2012; 18:6485-96; PMID:23032742; http://dx.doi.org/10.1158/1078-0432.CCR-12-1516.